Victory Capital Management Inc. trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 714,321 shares of the specialty pharmaceutical company's stock after selling 28,550 shares during the quarter. Victory Capital Management Inc. owned 1.29% of Supernus Pharmaceuticals worth $25,830,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the business. Pacer Advisors Inc. grew its stake in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company's stock worth $54,655,000 after buying an additional 403,028 shares in the last quarter. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after acquiring an additional 74,438 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 5.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after acquiring an additional 40,968 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Supernus Pharmaceuticals by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock worth $14,449,000 after purchasing an additional 27,134 shares during the period. Finally, Principal Financial Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 4.0% in the fourth quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company's stock worth $10,730,000 after purchasing an additional 11,321 shares during the last quarter.
Supernus Pharmaceuticals Stock Down 1.5 %
NASDAQ:SUPN traded down $0.49 during mid-day trading on Wednesday, hitting $31.53. 693,896 shares of the stock traded hands, compared to its average volume of 546,067. The business's 50-day moving average price is $36.54 and its 200 day moving average price is $35.25. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market cap of $1.76 billion, a PE ratio of 29.51 and a beta of 0.83.
Insider Transactions at Supernus Pharmaceuticals
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday.
Check Out Our Latest Stock Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Company Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
